

## References

### I-225

1. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use [package insert]. Genentech, Inc. South San Francisco, CA. Revised 06/2020.
2. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Pertuzumab/Trastuzumab/Hyaluronidase-zzxf. 2020.
3. Micromedex®Solutions Compendia. 2020. Pertuzumab/Trastuzumab/Hyaluronidase-zzxf.
4. National Comprehensive Cancer Network (NCCN). Pertuzumab, trastuzumab, and hyaluronidase-zzxf. NCCN Drugs and Biologics Compendium®. 2020.
5. Woodward N, De Boer RH, Redfern A, et al. Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE). *Clinical Breast Cancer*. 2019;19(3):216-224.
6. Kirschbrown WP, Kågedal M, Wang B, et al. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study. *Journal of Clinical Pharmacology*. 2019;59(5):702-716.